Retrospective clinical analysis of 133 cases of stage IV esophageal cancer

中华放射肿瘤学杂志 Pub Date : 2020-02-15 DOI:10.3760/CMA.J.ISSN.1004-4221.2020.02.005

Junjun Guo, W. Gao, Qian Wang, Shenbo Fu, P. Xi

{"title":"Retrospective clinical analysis of 133 cases of stage IV esophageal cancer","authors":"Junjun Guo, W. Gao, Qian Wang, Shenbo Fu, P. Xi","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.02.005","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer. \n \n \nMethods \nClinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed. All patients were assigned into the radiochemotherapy (n=89) and chemotherapy groups (n=44). The survival analysis was performed by Kaplan-Meier method. The multivariate prognostic analysis was conducted by Cox’s regression model. \n \n \nResults \nThe 1-, 2-and 3-year overall survival rates of the entire cohort were 53.5%, 20.4% and13.6% respectively. Cox’s regression analysis showed that gender, ECOG score, number of distant metastases, and whether the primary lesions received radiotherapy were the independent prognostic factors (all P 50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05), 8.6 months and 2.8 months for the PFS (P<0.05), and 15.2 months and 4.7 months for the LRFS (P<0.05), respectively. The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05). \n \n \nConclusion \nRadiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer. \n \n \nKey words: \nEsophageal neoplasm/radiochemotherapy; Esophageal neoplasm/chemotherapy; Prognosis","PeriodicalId":10288,"journal":{"name":"中华放射肿瘤学杂志","volume":"29 1","pages":"102-105"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华放射肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.02.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer. Methods Clinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed. All patients were assigned into the radiochemotherapy (n=89) and chemotherapy groups (n=44). The survival analysis was performed by Kaplan-Meier method. The multivariate prognostic analysis was conducted by Cox’s regression model. Results The 1-, 2-and 3-year overall survival rates of the entire cohort were 53.5%, 20.4% and13.6% respectively. Cox’s regression analysis showed that gender, ECOG score, number of distant metastases, and whether the primary lesions received radiotherapy were the independent prognostic factors (all P 50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05), 8.6 months and 2.8 months for the PFS (P<0.05), and 15.2 months and 4.7 months for the LRFS (P<0.05), respectively. The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05). Conclusion Radiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer. Key words: Esophageal neoplasm/radiochemotherapy; Esophageal neoplasm/chemotherapy; Prognosis

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

133例癌症IV期临床回顾性分析

目的探讨放疗治疗癌症Ⅳ期的临床意义。方法回顾性分析我院2012～2018年收治的133例食管癌症Ⅳ期患者的临床资料。所有患者被分为放化疗组（n=89）和化疗组（n=44）。生存率分析采用Kaplan-Meier法。采用Cox回归模型进行多因素预后分析。结果整个队列的1、2和3年总生存率分别为53.5%、20.4%和3.6%。Cox回归分析显示，性别、ECOG评分、远处转移灶数量和原发灶是否接受放疗是独立的预后因素（所有P 50Gy和≤50Gy分别为14.3个月和8.2个月（P<0.05），PFS分别为8.6个月和2.8个月（P<0.01），LRFS分别为15.2个月和4.7个月（P<0.05）。放化疗组的远处转移数和原发灶的临床疗效是独立的预后因素（均P＜0.05）。关键词：食管肿瘤/放化疗；食道肿瘤/化疗；预后

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中华放射肿瘤学杂志

自引率

0.00%

发文量

6375

期刊介绍： The Chinese Journal of Radiation Oncology is a national academic journal sponsored by the Chinese Medical Association. It was founded in 1992 and the title was written by Chen Minzhang, the former Minister of Health. Its predecessor was the Chinese Journal of Radiation Oncology, which was founded in 1987. The journal is an authoritative journal in the field of radiation oncology in my country. It focuses on clinical tumor radiotherapy, tumor radiation physics, tumor radiation biology, and thermal therapy. Its main readers are middle and senior clinical doctors and scientific researchers. It is now a monthly journal with a large 16-page format and 80 pages of text. For many years, it has adhered to the principle of combining theory with practice and combining improvement with popularization. It now has columns such as monographs, head and neck tumors (monographs), chest tumors (monographs), abdominal tumors (monographs), physics, technology, biology (monographs), reviews, and investigations and research.